Integrated Clinical and Prognostic Analysis of the m6A RNA Methylation Regulator YTHDF3 in Pan-Cancer and its Correlation with Cancer Cell Proliferation
Rattachement africain : cn. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Background: N6-methyladenosine (m 6 A) is the most abundant and extensive chemical modification of mammalian RNA molecules.Although numerous studies have investigated m 6 A methylation-related genes, to the best of our knowledge, none have examined the expression patterns of YTH N6-methyladenosine RNA binding protein 3 (YTHDF3) across cancers.Methods: Using various publicly available datasets, we searched for a potential carcinogenic role of YTHDF3 in 33 tumor types.Furthermore, the clinicopathological parameters, clinical prognostic value, enrichment analysis, mutations, microsatellite instability (MSI), tumor mutation burden (TMB), levels of infiltrating cells, and related immune checkpoint genes were included.Finally, we performed a validation analysis using existing clinical samples and proliferation-related functional experiments.Results: YTHDF3 is highly expressed in most cancer types and associated with patient prognosis in certain tumors.The ROC analysis suggested that YTHDF3 has high diagnostic value in 13 types of cancer.Furthermore, we found that the genes associated with YTHDF3 were enriched for translation initiation and mRNA metabolic processes.The results of the GSEA enrichment suggest that YTHDF3 may be associated with different pathways in cells in various tumor types.We further analyzed the correlations between YTHDF3 expression and MSI, TMB, and immune checkpoint genes.YTHDF3 also possibly exerts important antitumor immunotherapy effects.Additionally, the results of the immune analysis using TIMER showed that high YTHDF3 expression levels in pan-cancer tissues were related to an immunosuppressive microenvironment.Finally, we experimentally demonstrated that both overexpression and downregulation of YTHDF3 can affect cancer cell proliferation rates.Conclusion: YTHDF3 is a promising biomarker for cancer diagnosis.This study provides the first comprehensive pan-cancer report on YTHDF3 and increases our understanding of its oncogenic role in different tumors.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé, mais le titre doit être comparé manuellement.
- Titre Crossref
- Integrated Clinical and Prognostic Analysis of the m<sup>6</sup>A RNA Methylation Regulator YTHDF3 in Pan-Cancer and its Correlation with Cancer Cell Proliferation
- Date Crossref
- 01/01/2022
- Éditeur
- Ivyspring International Publisher
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Anhui University of Science and Technology pays non établi dans la noticeUniversité ou école supérieure
-
Shanghai Chest Hospital pays non établi dans la noticeÉtablissement de santé
-
Jiangsu Ocean University pays non établi dans la noticeUniversité ou école supérieure
-
Shanghai University of Traditional Chinese Medicine pays non établi dans la noticeUniversité ou école supérieure
-
School of Medicine Department of Clinical Laboratory Medicine pays non établi dans la noticeUniversité ou école supérieure
-
Lifang Ma pays non établi dans la noticeInstitution
-
No. 241 pays non établi dans la noticeInstitution
-
Shanghai University of Traditional Chineses Medicine pays non établi dans la noticeUniversité ou école supérieure
Anhui University of Science and Technology, Shanghai Chest Hospital et Jiangsu Ocean University, avec 5 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.